BOSTON SCIENTIFIC CORP

NYSE: BSX (Boston Scientific Corporation)

Last update: 14 May, 5:37PM

102.95

0.00 (0.00%)

  • 1D 0.00%
  • 5D -1.77%
  • 1M 1.03%
  • 6M 15.35%
  • YTD 15.18%
  • 1Y 36.96%
  • 5Y 184.47%
Previous Close 102.95
Open 102.99
Volume 5,737,584
Avg. Volume (3M) 8,544,491
Market Cap 152,309,366,784
Price / Earnings (TTM) 75.15
Price / Earnings (Forward) 35.97
Price / Sales 8.89
Price / Book 6.98
52 Weeks Range
71.88 (-30%) — 107.17 (4%)
Earnings Date 22 Jul 2025 - 28 Jul 2025
Profit Margin 11.58%
Operating Margin (TTM) 20.09%
Diluted EPS (TTM) 1.37
Quarterly Revenue Growth (YOY) 20.90%
Quarterly Earnings Growth (YOY) 36.20%
Total Debt/Equity (MRQ) 52.16%
Current Ratio (MRQ) 1.45
Operating Cash Flow (TTM) 3.81 B
Levered Free Cash Flow (TTM) 2.32 B
Return on Assets (TTM) 5.28%
Return on Equity (TTM) 9.50%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Bearish Mixed
Medical Devices (Global) Bearish Mixed
Stock Boston Scientific Corporation Mixed Bullish

AIStockmoo Score

1.9
Analyst Consensus 2.0
Insider Activity NA
Price Volatility -0.5
Technical Moving Averages 3.5
Technical Oscillators 2.5
Average 1.88

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BSX 152 B - 75.15 6.98
SYK 146 B 0.87% 51.57 6.90
PHG 24 B - - 1.72
ABT 231 B 1.27% 17.25 4.72
MDT 103 B 3.47% 22.35 2.21
EW 42 B - 30.39 4.47

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Sector Healthcare
Industry Medical Devices
Investment Style Large Core
% Held by Insiders 0.19%
% Held by Institutions 92.82%

Ownership

Name Date Shares Held
Bollard Group Llc 31 Dec 2024 20,733,226
52 Weeks Range
71.88 (-30%) — 107.17 (4%)
Price Target Range
112.00 (8%) — 125.00 (21%)
High 125.00 (Morgan Stanley, 21.42%) Buy
125.00 (Citigroup, 21.42%) Buy
125.00 (Barclays, 21.42%) Buy
Median 120.00 (16.56%)
Low 112.00 (Evercore ISI Group, 8.79%) Buy
Average 119.88 (16.45%)
Total 8 Buy
Avg. Price @ Call 101.69
Firm Date Target Price Call Price @ Call
Citigroup 22 May 2025 125.00 (21.42%) Buy 102.95
Morgan Stanley 16 May 2025 125.00 (21.42%) Buy 102.95
Barclays 25 Apr 2025 125.00 (21.42%) Buy 101.90
Baird 24 Apr 2025 120.00 (16.56%) Buy 101.14
Evercore ISI Group 24 Apr 2025 112.00 (8.79%) Buy 101.14
Needham 24 Apr 2025 115.00 (11.70%) Buy 101.14
16 Apr 2025 113.00 (9.76%) Buy 95.25
RBC Capital 24 Apr 2025 120.00 (16.56%) Buy 101.14
Truist Securities 24 Apr 2025 117.00 (13.65%) Buy 101.14
11 Apr 2025 113.00 (9.76%) Buy 93.67

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria